Avalyn is developing inhaled therapies for people with severe and rare respiratory diseases.

Our lead asset, AP01, is an aerosolized formulation of pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF). AP01 is designed to maximize pirfenidone’s potential by limiting the adverse effects associated with systemic exposure and delivering an optimized dose directly to the lungs.